Suppr超能文献

糖皮质激素性骨质疏松症

Glucocorticoid-induced osteoporosis.

作者信息

Saag Kenneth G

机构信息

Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, 1813 Sixth Avenue South, Birmingham, AL 35294-3296, USA.

出版信息

Endocrinol Metab Clin North Am. 2003 Mar;32(1):135-57, vii. doi: 10.1016/s0889-8529(02)00064-6.

Abstract

Therapeutic use of glucocorticoids can lead to many well-known adverse events. Of all potential serious side effects, glucocorticoid-induced osteoporosis (GIOP) is one of the most devastating complications of protracted glucocorticoid therapy in rheumatoid arthritis. GIOP is the most common form of drug-induced osteoporosis. Although much has been written about the association of glucocorticoids with bone disease among patients with chronic inflammatory conditions, many issues remain unsettled. This article focuses on areas of continued controversies, including the epidemiology and pathogenesis of GIOP, specification of a "safe" dose, methods for diagnosis of GIOP, and an evidence-based approach for GIOP prevention.

摘要

糖皮质激素的治疗应用可导致许多众所周知的不良事件。在所有潜在的严重副作用中,糖皮质激素诱导的骨质疏松症(GIOP)是类风湿关节炎长期糖皮质激素治疗最具破坏性的并发症之一。GIOP是药物性骨质疏松症最常见的形式。尽管关于慢性炎症性疾病患者中糖皮质激素与骨病的关联已有大量著述,但许多问题仍未解决。本文聚焦于持续存在争议的领域,包括GIOP的流行病学和发病机制、“安全”剂量的确定、GIOP的诊断方法以及基于证据的GIOP预防方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验